Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study. 2018

Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Pseudomonas aeruginosa (P. aeruginosa) occupies an important niche in the pathogenic microbiome of bronchiectasis. The objective of this study is to evaluate the clinical characteristics and prognostic value of P. aeruginosa in Chinese adult patients with bronchiectasis. This retrospective and follow-up study enrolled 1188 patients diagnosed with bronchiectasis at Shanghai Pulmonary Hospital between January 2011 and December 2012. The patients' clinical data including anthropometry, clinical symptoms, serum biomarkers, radiographic manifestations and lung function indices were reviewed. The median follow-up duration (IQR) was 44 (40-54) months, during which 289 patients were lost to follow-up. Data from 899 patients were collected and analysed for the outcomes of mortality, annual exacerbation frequency and health-related quality of life. P. aeruginosa was isolated from 232 patients, alongside other pathogens such as Aspergillus (n=75) and Candida albicans (n=72). There were 74 deaths (12% of patients with P. aeruginosa, 7.3% of those without) over the course of the follow-up. The isolation of P. aeruginosa was a risk factor for all-cause mortality (HR, 3.07; 95% CI 1.32 to 7.15) and was associated with high rates of exacerbations (ie, ≥3 exacerbations per year of follow-up) (HR, 2.40; 95% CI 1.20 to 4.79). Patients with P. aeruginosa also had worse scores on the Hospital Anxiety and Depression Scale (anxiety, p=0.005; depression, p<0.001), the Leicester Cough Questionnaire (p=0.033) and the modified Medical Research Council scale (p=0.001) compared with those without P. aeruginosa. Isolation of P. aeruginosa in patients with bronchiectasis is a significant prognostic indicator and should be a major factor in the clinical management of the disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D001987 Bronchiectasis Persistent abnormal dilatation of the bronchi. Cylindrical Bronchiectasis,Cystic Bronchiectasis,Saccular Bronchiectasis,Varicose Bronchiectasis,Bronchiectases,Bronchiectasis, Cylindrical,Bronchiectasis, Cystic,Bronchiectasis, Saccular,Bronchiectasis, Varicose,Cylindrical Bronchiectases,Cystic Bronchiectases,Saccular Bronchiectases,Varicose Bronchiectases
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
January 2019, Respiratory medicine,
Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
January 2021, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia,
Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
August 2016, Respiratory medicine,
Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
January 2015, Respiration; international review of thoracic diseases,
Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
December 2016, Microbiology (Reading, England),
Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
June 2019, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
June 2010, Thorax,
Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
March 2015, Pathogens and disease,
Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
September 2001, Thorax,
Hong Wang, and Xiao-Bin Ji, and Bei Mao, and Cheng-Wei Li, and Hai-Wen Lu, and Jin-Fu Xu
January 2005, The Annals of pharmacotherapy,
Copied contents to your clipboard!